MX391141B - Anticuerpos anti-ceramida. - Google Patents
Anticuerpos anti-ceramida.Info
- Publication number
- MX391141B MX391141B MX2017001686A MX2017001686A MX391141B MX 391141 B MX391141 B MX 391141B MX 2017001686 A MX2017001686 A MX 2017001686A MX 2017001686 A MX2017001686 A MX 2017001686A MX 391141 B MX391141 B MX 391141B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- ceramide
- disclosed
- ceramide antibodies
- apoptosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034453P | 2014-08-07 | 2014-08-07 | |
| PCT/US2015/044144 WO2016022883A1 (en) | 2014-08-07 | 2015-08-07 | Anti-ceramide antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001686A MX2017001686A (es) | 2017-09-01 |
| MX391141B true MX391141B (es) | 2025-03-21 |
Family
ID=55264608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001686A MX391141B (es) | 2014-08-07 | 2015-08-07 | Anticuerpos anti-ceramida. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10450385B2 (enExample) |
| EP (1) | EP3177650B1 (enExample) |
| JP (1) | JP6670297B2 (enExample) |
| KR (1) | KR102296416B1 (enExample) |
| CN (1) | CN107074949B (enExample) |
| AU (1) | AU2015300902B2 (enExample) |
| CA (1) | CA2957415C (enExample) |
| IL (1) | IL250374B (enExample) |
| MX (1) | MX391141B (enExample) |
| RU (1) | RU2717651C2 (enExample) |
| SG (1) | SG11201700787XA (enExample) |
| WO (1) | WO2016022883A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017228474C1 (en) | 2016-03-04 | 2024-03-28 | Abmuno Therapeutics Llc | Antibodies to TIGIT |
| CN110121507B (zh) * | 2016-12-23 | 2024-04-05 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| WO2020231629A1 (en) | 2019-05-16 | 2020-11-19 | Snake River Bioscience, Inc. | Compositions and methods for the treatment of major depressive disorder |
| KR102808557B1 (ko) * | 2019-06-06 | 2025-05-14 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Cd73에 특이적인 결합 분자 및 결합 분자의 용도 |
| US10975169B1 (en) | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| KR102245082B1 (ko) * | 2020-02-14 | 2021-04-26 | 단국대학교 천안캠퍼스 산학협력단 | 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도 |
| CA3172201A1 (en) * | 2020-03-18 | 2021-09-23 | Arthur Tinkelenberg | Anti-ceramide antibodies |
| KR20230019152A (ko) | 2020-06-02 | 2023-02-07 | 아르커스 바이오사이언시즈 인코포레이티드 | Tigit에 대한 항체 |
| BR112023018758A2 (pt) * | 2021-03-16 | 2023-11-28 | Univ Michigan State | Intensificação de cicatrização de ferida com anticorpos anticeramida |
| WO2024226646A2 (en) * | 2023-04-25 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Dlk1 -targeting antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| JPH02128697A (ja) * | 1988-11-09 | 1990-05-17 | Hoechst Japan Ltd | 抗フコシルセラミドモノクローナル抗体 |
| US7897753B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
| RU2310393C1 (ru) * | 2006-02-16 | 2007-11-20 | ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации | Способ прогнозирования обострений лепрозных невропатий у больных лепрой |
| EP2152287B1 (en) * | 2007-05-06 | 2014-04-02 | Sloan Kettering Institute For Cancer Research | Methods for treating and preventing gi syndrome and graft versus host disease |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US8410251B2 (en) * | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| JP5812418B2 (ja) * | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| FR2971250A1 (fr) | 2011-02-07 | 2012-08-10 | Univ Nantes | Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese |
| KR101256351B1 (ko) | 2011-11-22 | 2013-04-19 | 김석진 | 필터 삽입공을 갖는 카메라 후드 |
| MX357505B (es) * | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| DK2854850T3 (da) * | 2012-05-25 | 2021-08-30 | Sloan Kettering Inst Cancer Res | Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom |
| CA3172201A1 (en) * | 2020-03-18 | 2021-09-23 | Arthur Tinkelenberg | Anti-ceramide antibodies |
-
2015
- 2015-08-07 MX MX2017001686A patent/MX391141B/es unknown
- 2015-08-07 CA CA2957415A patent/CA2957415C/en active Active
- 2015-08-07 EP EP15830378.4A patent/EP3177650B1/en active Active
- 2015-08-07 KR KR1020177006255A patent/KR102296416B1/ko active Active
- 2015-08-07 RU RU2017105596A patent/RU2717651C2/ru active
- 2015-08-07 AU AU2015300902A patent/AU2015300902B2/en active Active
- 2015-08-07 SG SG11201700787XA patent/SG11201700787XA/en unknown
- 2015-08-07 WO PCT/US2015/044144 patent/WO2016022883A1/en not_active Ceased
- 2015-08-07 CN CN201580048151.7A patent/CN107074949B/zh active Active
- 2015-08-07 US US15/502,162 patent/US10450385B2/en active Active
- 2015-08-07 JP JP2017506827A patent/JP6670297B2/ja active Active
-
2017
- 2017-01-31 IL IL250374A patent/IL250374B/en active IP Right Grant
-
2019
- 2019-09-11 US US16/568,152 patent/US11447572B2/en active Active
-
2022
- 2022-08-15 US US17/887,952 patent/US20230416409A1/en not_active Abandoned
-
2024
- 2024-07-31 US US18/790,647 patent/US20250197524A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10450385B2 (en) | 2019-10-22 |
| RU2717651C2 (ru) | 2020-03-24 |
| US20250197524A1 (en) | 2025-06-19 |
| EP3177650A1 (en) | 2017-06-14 |
| JP2017527544A (ja) | 2017-09-21 |
| IL250374B (en) | 2021-04-29 |
| NZ728981A (en) | 2024-03-22 |
| AU2015300902A1 (en) | 2017-03-02 |
| CN107074949A (zh) | 2017-08-18 |
| US20230416409A1 (en) | 2023-12-28 |
| US20190389970A1 (en) | 2019-12-26 |
| EP3177650A4 (en) | 2018-01-03 |
| EP3177650B1 (en) | 2025-11-05 |
| US20170335014A1 (en) | 2017-11-23 |
| JP6670297B2 (ja) | 2020-03-18 |
| IL250374A0 (en) | 2017-03-30 |
| CA2957415C (en) | 2021-07-13 |
| US11447572B2 (en) | 2022-09-20 |
| RU2017105596A3 (enExample) | 2019-04-17 |
| WO2016022883A1 (en) | 2016-02-11 |
| CN107074949B (zh) | 2021-06-15 |
| BR112017002433A2 (pt) | 2017-11-28 |
| MX2017001686A (es) | 2017-09-01 |
| KR102296416B1 (ko) | 2021-09-01 |
| KR20170066327A (ko) | 2017-06-14 |
| AU2015300902B2 (en) | 2020-05-28 |
| CA2957415A1 (en) | 2016-02-11 |
| RU2017105596A (ru) | 2018-09-07 |
| SG11201700787XA (en) | 2017-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391141B (es) | Anticuerpos anti-ceramida. | |
| PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| IL259924A (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| HUE061842T2 (hu) | A rák kezelésének módszerei anti-PD-1 antitestekkel | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| IL251537A0 (en) | Human anti-ox40 antibodies and their uses | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| DK3157959T3 (da) | Monoklonale antistoffer mod her2-epitop og fremgangsmåder til anvendelse deraf | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
| HUE050831T2 (hu) | Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EP3244926C0 (en) | TREATMENT OF CANCER WITH ANTI-LAP MONOCLONAL ANTIBODIES | |
| DK3119808T3 (da) | Antistofsammensætninger til tumorbehandling | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| IL248402A0 (en) | Humanized antibodies against ceacam1 | |
| DK3280440T3 (da) | Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
| CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
| DK3154583T3 (da) | Humane monoklonale antistoffer mod gangliosid gd2 | |
| IL252535A0 (en) | A combination of cs1 and pd1 antibodies for the treatment of cancer (myeloma) |